Brave Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Brave Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,600	Closed	-$36K	–	409
2016 Q2	$36K	Hold	4,600	–	–	0.02%	249
2016 Q1	$36K	Hold	4,600	–	–	0.03%	248
2015 Q4	$50K	Hold	4,600	–	–	0.03%	220
2015 Q3	$32K	Sell	4,600 -9,500	-67%	-$77.4K	0.02%	249
2015 Q2	$125K	Buy	14,100 +4,000	+40%	+$37.8K	0.09%	155
2015 Q1	$100K	Buy	10,100 +6,100	+153%	+$76.2K	0.07%	169
2014 Q4	$49K	Hold	4,000	–	–	0.04%	228
2014 Q3	$40K	Hold	4,000	–	–	0.03%	237
2014 Q2	$30K	Hold	4,000	–	–	0.02%	268
2014 Q1	$13K	Hold	4,000	–	–	0.01%	333
2013 Q4	$13K	Buy	+4,000	New	+$11.6K	0.01%	325

Other funds holding ACHN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brave Asset Management's ACHN Position: Q3 2016 in Review

Brave Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2016, closing a stake of 4,600 shares — an estimated $36K sold.

Brave Asset Management first reported a position in ACHN in Q4 2013 and held it in 11 quarters. The position peaked at $125K in Q2 2015. 162 funds tracked by Wall St. Rank hold ACHN as of Q3 2016.

Brave Asset Management reported no remaining Achillion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Brave Asset Management sold 4,600 Achillion Pharmaceuticals shares in Q3 2016, an estimated $36K.
Brave Asset Management first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 11 quarters.
Brave Asset Management's Achillion Pharmaceuticals position peaked at $125K in Q2 2015.
162 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2016.

Based on Brave Asset Management's 13F filing for Q3 2016, filed 10 Nov 2016.